Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Free Report) have been assigned an average rating of “Moderate Buy” from the twenty-one ratings firms that are presently covering the firm, Marketbeat Ratings reports. Eight analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $105.26.
Several analysts recently issued reports on BMRN shares. Canaccord Genuity Group reiterated a “hold” rating and set a $89.00 target price on shares of BioMarin Pharmaceutical in a report on Thursday, July 25th. TD Cowen cut their price objective on BioMarin Pharmaceutical from $125.00 to $120.00 and set a “buy” rating for the company in a report on Tuesday, August 6th. Cantor Fitzgerald restated an “overweight” rating and set a $110.00 target price on shares of BioMarin Pharmaceutical in a report on Monday, August 5th. Morgan Stanley cut their price target on shares of BioMarin Pharmaceutical from $115.00 to $112.00 and set an “overweight” rating for the company in a research note on Friday, April 26th. Finally, StockNews.com upgraded shares of BioMarin Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th.
View Our Latest Analysis on BioMarin Pharmaceutical
Insider Buying and Selling at BioMarin Pharmaceutical
Hedge Funds Weigh In On BioMarin Pharmaceutical
Hedge funds and other institutional investors have recently modified their holdings of the business. AMI Asset Management Corp boosted its stake in BioMarin Pharmaceutical by 51.9% in the first quarter. AMI Asset Management Corp now owns 346,189 shares of the biotechnology company’s stock valued at $30,236,000 after buying an additional 118,230 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in shares of BioMarin Pharmaceutical by 7,368.7% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 60,571 shares of the biotechnology company’s stock worth $5,840,000 after acquiring an additional 59,760 shares during the last quarter. ING Groep NV acquired a new stake in shares of BioMarin Pharmaceutical in the 4th quarter valued at approximately $20,248,000. Fisher Asset Management LLC bought a new stake in shares of BioMarin Pharmaceutical during the 4th quarter valued at approximately $1,301,000. Finally, APG Asset Management US Inc. acquired a new position in BioMarin Pharmaceutical during the 4th quarter worth approximately $3,462,000. Institutional investors own 98.71% of the company’s stock.
BioMarin Pharmaceutical Price Performance
Shares of BMRN stock opened at $90.02 on Friday. The firm’s fifty day moving average price is $85.48 and its two-hundred day moving average price is $84.97. The company has a current ratio of 2.74, a quick ratio of 1.70 and a debt-to-equity ratio of 0.12. BioMarin Pharmaceutical has a 1 year low of $73.68 and a 1 year high of $99.56. The firm has a market capitalization of $17.09 billion, a P/E ratio of 84.13, a PEG ratio of 1.20 and a beta of 0.32.
BioMarin Pharmaceutical Company Profile
BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
Read More
- Five stocks we like better than BioMarin Pharmaceutical
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Lumen: Among Top Performers Last Month, Still Has Warning Signs
- How to Calculate Inflation Rate
- Baidu’s Strong Quarter Proves a Smart Pick for Michael Burry
- What Is WallStreetBets and What Stocks Are They Targeting?
- Intuit Beats Q4 Earnings: AI, Dividends, and a Growth Strategy
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.